Dr. Manisha Shah on Cabozantinib Impact on Tumor Shrinkage in Differentiated Thyroid Cancer

Manisha Shah, MD
Published: Tuesday, Oct 20, 2015



Manisha Shah, MD, professor of Oncology, Ohio State University Medical Center, discusses cabozantinib in patients with radioiodine- refractory differentiated thyroid cancer.

The study looked at 25 patients with radioiodine-refractory differentiated thyroid cancer who had progressed on prior VEGF receptor-targeted therapy. The study was designed with the goal of five out of the 25 patients achieving a partial response, explains Shah. However, the trial exceeded these expectations, with nine patients achieving significant tumor shrinkage and two other patients having some tumor shrinkage.

Based on these results, it appears that cabozantinib may be an effective second- or third-line therapy for patients with radioiodine-refractory differentiated thyroid cancer, says Shah.

<<< View more from the 2015 International Thyroid Congress



Manisha Shah, MD, professor of Oncology, Ohio State University Medical Center, discusses cabozantinib in patients with radioiodine- refractory differentiated thyroid cancer.

The study looked at 25 patients with radioiodine-refractory differentiated thyroid cancer who had progressed on prior VEGF receptor-targeted therapy. The study was designed with the goal of five out of the 25 patients achieving a partial response, explains Shah. However, the trial exceeded these expectations, with nine patients achieving significant tumor shrinkage and two other patients having some tumor shrinkage.

Based on these results, it appears that cabozantinib may be an effective second- or third-line therapy for patients with radioiodine-refractory differentiated thyroid cancer, says Shah.

<<< View more from the 2015 International Thyroid Congress




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x